LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Toumi, Mondher; Ricciardi, Walter (2015)
Publisher: Journal of Market Access & Health Policy
Journal: Journal of Market Access & Health Policy
Languages: English
Types: Article
Subjects:
--(Published: 12 August 2015)Citation: Journal of Market Access & Health Policy 2015, 3: 29204 - http://dx.doi.org/10.3402/jmahp.v3.29204
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. World Health Organisation (2011). Global Alliance for Vaccines and Immunization. Fact Sheet N8169. Available from: http://www.who.int/mediacentre/factsheets/fs169/en/ [cited 10 July 2015].
    • 2. Ehreth J. The economics of vaccination from a global perspective: Present and future. 2 3 December, 2004, Vaccines: All things considered, San Francisco, CA, USA. Expert Rev Vaccines. 2005; 4(1): 19 21.
    • 3. Wicker S, Maltezou HC. Vaccine-preventable diseases in Europe: Where do we stand? Expert Rev Vaccines. 2014; 13(8): 979 87.
    • 4. Bloom DE, Canning D, Weston M. The value of vaccination. World Econ. 2005; 6(3): 15 35.
    • 5. Loeppke R, Nicholson S, Taitel M, Sweeney M, Haufle V, Kessler RC. The impact of an integrated population health enhancement and disease management program on employee health risk, health conditions, and productivity. Popul Health Manag. 2008; 11(6): 287 96.
    • 6. Suhrcke M, McKee M, Stuckler D, Sauto Arce R, Tsolova S, Mortensen J. The contribution of health to the economy in the European Union. Public Health. 2006; 120(11): 994 1001.
    • 7. Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012; 12: 878.
    • 8. Whitney CG, Zhou F, Singleton J, Schuchat A. Benefits from immunization during the vaccines for children program era United States, 1994 2013. MMWR Morb Mortal Wkly Rep. 2014; 63(16): 352 5.
    • 9. Ehreth J. The global value of vaccination. Vaccine. 2003; 21(7 8): 596 600.
    • 10. OECD. Health at a glance 2011: OECD indicators. Available from: http://www.oecd.org/els/health-systems/49105858.pdf [cited 3 July 2015].
    • 11. Barnighausen T, Bloom DE, Canning D, Friedman A, Levine OS, O'Brien J, et al. Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine. Vaccine. 2011; 29(13): 2371 80.
    • 12. Beutels P. Economic evaluation of vaccination programmes in humans: A methodological exploration with application to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. Antwerp: University of Antwerp; 2002.
    • 13. Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP. The costeffectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine. 2012; 30(48): 6766 76.
    • 14. Vitale F, Barbieri M, Dirodi B, Vitali Rosati G, Franco E. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at national and regional level in Italy]. Ann Ig. 2013; 25(1): 43 56.
    • 15. Public Health England. Early evidence of the impact of the national rotavirus immunisation programme. Health Prot Rep Wkly Rep 2014; 8(12): 9 10.
    • 16. Public Health England. Invasive meningococcal infections laboratory reports in England and Wales. Available from: https:// www.gov.uk/government/uploads/system/uploads/attachment_ data/file/343375/Table_1a_Invasive_meningococcal__E_W_by_ capsular_group___epi_year.pdf [cited 28 June 2015].
    • 17. Public Health England. 10 years of meningitis C vaccine: Outstanding health protection measure of the past decade. Available from: http://webarchive.nationalarchives.gov.uk/2014 0714084352/http://www.hpa.org.uk/NewsCentre/NationalPress Releases/2009PressReleases/09112310yearsofmeningitisCvaccine/ [cited 29 June 2015].
    • 18. Dasbach E, Insinga R, Elbasha E. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG. 2008; 115(8): 947 56.
    • 19. Council of the European Union. Council conclusions on vaccinations as an effective tool in public health. Brussels: Council of the European Union; 2014.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article

Collected from